Article
Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society - 1 Jan 2000
Wu W, Celestino J, Milam M R, Schmeler K M, Broaddus R R, Ellenson L H, Lu K H
Abstract excerpt
PTEN mutations have been implicated in the development of endometrial hyperplasia and subsequent cancer. Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists have demonstrated antineoplastic and chemopreventive effects. The purpose of this study was to evaluate the effects of the PPAR-gamma agonist rosiglitazone on both PTEN wild type and PTEN null cell lines and in the PTEN heterozygote((+/-))...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.